Morphine Kalceks (Morphine Hydrochloride Trihydrate)

Morphine acts on the μ‑opioid receptor pathway to provide potent analgesia for severe pain conditions.

• Acute postoperative pain: delivers rapid pain relief after surgical procedures.
• Cancer‑related pain: controls moderate to severe pain associated with malignant disease.
• Severe chronic non‑cancer pain: reduces persistent pain when other therapies are insufficient.
• Acute traumatic injury pain: alleviates intense pain from severe injuries.

• Morphine binds as an agonist to μ‑opioid receptors in the central nervous system, inhibiting the release of excitatory neurotransmitters and reducing neuronal excitability. This action diminishes the perception of pain and alters the emotional response to painful stimuli, producing analgesia without affecting the peripheral nociceptors directly.

Morphine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: feeling of sickness often accompanied by an urge to vomit.
• Constipation: reduced bowel movements and hard stools.
• Drowsiness: increased sleepiness or reduced alertness.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Itching: mild pruritus, especially at the injection site.
• Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be life‑threatening.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Anaphylaxis: rare allergic reaction with rash, swelling, and airway compromise.
• Adrenal insufficiency: impaired cortisol production with fatigue and weakness.
• Seizures: rare occurrence of convulsive episodes.

When using Morphine, clinicians should observe several safety measures to minimize risk.

• Dose titration: adjust the dose based on individual analgesic response and tolerance.
• Respiratory monitoring: continuously assess breathing, especially in opioid‑naïve patients.
• Addiction potential: evaluate risk of dependence before initiating therapy.
• Concurrent CNS depressants: avoid or use with caution when combined with other sedatives.
• Renal or hepatic impairment: consider dose reduction and close monitoring.
• Store below 25°C: keep in the original packaging, protect from light and moisture.

Morphine interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid)

• Respiratory depressants (e.g., benzodiazepines, barbiturates): may cause fatal respiratory depression.
• MAO inhibitors: increase risk of severe hypertension or serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): raise morphine plasma concentrations.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Anticholinergic agents: can exacerbate constipation.
• Diuretics: may enhance hypotensive effects when combined with morphine.